Cardiol Therapeutics CEO Discusses Supplier Agreement with Medical Cannabis by Shoppers
Cardiol Therapeutics CEO Discusses Supplier Agreement with Medical Cannabis by Shoppers
Cardiol Therapeutics Inc. (TSX:CRDL, OTCQX:CRTPF) CEO David Elsley discusses the supplier agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc. Shoppers will be the exclusive retailer of Cardiol’s CardiolRx™ brand of cannabidiol products in Canada. Under the terms of the agreement, Cardiol’s exclusive manufacturing partner, Dalton Pharma Services Inc., will supply Cardiol’s pharmaceutical cannabidiol products to Shoppers for resale in all provinces and territories in Canada through Shoppers’ online store. #health #ShoppersDrugMart #pharmaceutical
________________________________________________________________
Investing News Network (INN)
Find out more about investing by INN @
http://investingnews.com/
Want a FREE investor kit? Download here↓
https://bit.ly/31NNNTR
Follow us Facebook:
https://www.facebook.com/resourceinvestingnews
Follow us on Twitter:
@INN_Resource
________________________________________________________________
This interview is sponsored by Cardiol Therapeutics Inc. (TSX:CRDL, OTCQX:CRTPF). This interview provides information that was sourced by the Investing News Network (INN) and approved by Cardiol Therapeutics Inc. in order to help investors learn more about the company. Cardiol Therapeutics Inc. is a client of INN. The company’s campaign fees pay for INN to create and update this interview.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Cardiol Therapeutics Inc. and seek advice from a qualified investment advisor.
This interview may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, receipt of property titles, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The issuer relies upon litigation protection for forward-looking statements. Investing in companies comes with uncertainties as market values can fluctuate.